Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8960830 | 0.82 | MEN1 (0.39) | MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL20253507 | 0.80 | MEN1 (0.39) | MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL8153609 | 0.75 | ALOX15 (0.68) | MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL22931496 | 0.74 | MEN1 (0.32) | MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL5382187 | 0.74 | MEN1 (0.32) | MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL1472536 | 0.73 | MEN1 (0.46) | MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL8960797 | 0.73 | MEN1 (0.46) | MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL27959579 | 0.72 | MEN1 (0.45) | MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL790336 | 0.72 | — | — | |
| SCHEMBL8461628 | 0.72 | MEN1 (0.40) | MEN1CYP3A4ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337536-B1 | CATIONIC GROUP-3 CATALYST SYSTEM | EXXONMOBIL CHEM PATENTS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-7390861-B2 | Cationic group-3 catalyst system | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20040033891-A1 | Cationic group-3 catalyst system | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-02-19 | — | — | US | disclosed |
| EP-1337536-A1 | CATIONIC GROUP-3 CATALYST SYSTEM | ExxonMobil Chemical Patents Inc. (US) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002032909-A1 | CATIONIC GROUP-3 CATALYST SYSTEM | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033891-A1 | Cationic group-3 catalyst system | COG3, ORC3, LIG3 | MEN1 1242/4885CYP3A4 3164/4885ALOX15 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.